Drug research

IPH5201 + durvalumab + standard chemotherapy

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy; Durvalumab; MEDI4736, IMFINZI; Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy; Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607	Innate Pharma	Phase 2	Recruiting	2027-06Estimated

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Innate PharmaRecruitingPrimary completion: 2027-06 · Estimated

Trial details

Registry ID: NCT05742607
Phase: Phase 2

Regulatory dates and decisions

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.